GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Hosted on MSN20h
GSK lowered to hold by Jefferies, valuation disconnect citedJefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback